Status:
TERMINATED
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.
Detailed Description
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males. ...
Eligibility Criteria
Inclusion
- Medically healthy
- Male
- Right-handed aged
- 18-45 years
- BMI 17.5 to 35kg/m2.
Exclusion
- Females
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).
Key Trial Info
Start Date :
January 19 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 14 2016
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT02306876
Start Date
January 19 2015
End Date
June 14 2016
Last Update
August 17 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Arcadia MRI & Imaging Center
Arcadia, California, United States, 91007
2
California Clinical Trials Medical Group
Glendale, California, United States, 91206
3
Glendale Adventist Medical Center
Glendale, California, United States, 91206